Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 130,68€(−2,48%). Der Median liegt bei 130,68€(−2,48%).
Kaufen | 15 |
Halten | 15 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 3 / 15 |
HGI-Strategie | 4 / 18 |
Levermann-Strategie | -3 / 13 |
News
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.» Mehr auf zacks.com
Burn Care Market worth $3.35 billion by 2030 with 5.6% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Burn Care Market, valued at US$2.46 billion in 2024, is forecasted to grow at a robust CAGR of 5.6%, reaching US$2.55 billion in 2025 and an impressive US$3.35 billion by 2030. This market is experiencing consistent growth due to several key factors. The number of burn injuries is rising due to factors such as industrial accidents, domestic fires, and other hazards. Furthermore, advancements in treatment technologies and increased awareness and education about burn care contribute to this trend. Additionally, supportive government initiatives play a significant role in market development. The demand for effective burn treatments is rising as the global population ages. Older individuals are more susceptible to slow-healing wounds and burn complications, which, in turn, increases the need for advanced burn care products. Moreover, technological advancements in burn treatment—including innovative burn dressings, biologics, and advanced burn wound assessment devices—enhance treatment efficiency and effectiveness. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247121470 Browse in-depth TOC on "Burn Care Market" 345 - Tables 45 - Figures 302 - Pages By Based on products, the burn care market is categorized into five segments: advanced burn dressings, burn wound therapy devices, biologics, traditional burn care products, and other burn care products. Among these, the biologics segment is expected to register the highest CAGR during the forecast period. This growth is driven by the rising demand for advanced and effective treatment options for deep and complex burns. Biologics provide targeted healing, minimize long-term complications, and promote tissue regeneration, making them particularly suitable for treating severe burns. The increasing acceptance of these products among healthcare professionals and ongoing innovations in regenerative medicine are contributing to the strong and sustained growth of the biologics segment. By Based on burn degree, the burn care market is divided into first-degree burns (minor burns), second-degree burns (partial-thickness burns), and third-degree burns (full-thickness burns). Of these, the second-degree burns segment accounted for the largest market share of the burn care market in 2024. This is largely because partial-thickness burns occur more frequently. These burns tend to destroy the epidermis and dermis; as such, they require the application of advanced burn care products, which drives consistent demand in this segment. By geography, the market for burn care is divided into five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the burn care market in 2024 with the largest market share. This is primarily because countries like the US and Canada have well-developed healthcare facilities, supporting widespread access to advanced burn care products and treatments. The region also experiences a high rate of burn injuries. The availability of key players and constant investment in research & development further consolidate North America's position in the burn care market. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=247121470 The major players operating in this market are Smith+Nephew (UK), Mölnlycke Health Care AB (Sweden), Cardinal Health Inc. (US), Integra LifeSciences Holdings Corporation (US), ConvaTec Group Plc (UK), Coloplast Group (Denmark), Solventum Corporation (US), Essity Aktiebolag (Sweden), PAUL HARTMANN AG (Germany), and Organogenesis Holdings Inc. (US). SMITH+NEPHEW (UK) Smith+Nephew is distinguished by its advanced wound care solutions and robust research and development capabilities, enabling it to provide effective burn care products. Mölnlycke Health Care AB has solidified its market position through strategic partnerships. Cardinal Health Inc. utilizes its extensive distribution network and diverse product line to reach a wide range of healthcare facilities, thereby increasing its share in the burn care market. Integra LifeSciences Holdings Corporation is recognized for its broad range of biologics that offer crucial support for severe burns. ConvaTec Group Plc has strengthened its market presence through global expansion and strategic acquisitions. MOLNLYCKE HEALTH CARE AB (SWEDEN): Mölnlycke Health Care AB also boasts a comprehensive product portfolio in the advanced wound care market. The company's leading position in this sector is largely due to its robust global sales and distribution network, which allows it to effectively market its products in various countries. Mölnlycke primarily utilizes inorganic strategies, such as partnerships, to maintain its market position. For example, in May 2024, the company formed a new partnership with the Phoenix Society, a burn survivor organization in the US. Through this collaboration, Mölnlycke will support the Phoenix Society's initiatives with its extensive range of burn care solutions For more information, Inquire Now! Related Reports: Wound Care Biologics Market Advanced Wound Care Market Point of Care Diagnostics Market Wound Care Market Point of Care Molecular Diagnostics Market Get access to the latest updates on Burn Care Companies and Burn Care Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg» Mehr auf prnewswire.com
Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks
Cardinal Health Inc. CAH on Thursday reported third-quarter 2025 adjusted EPS of $2.35, up 13% year over year, beating the consensus of $2.17.» Mehr auf benzinga.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 50,73 Mrd | 0,30% |
Bruttoeinkommen | 1,96 Mrd | 12,48% |
Nettoeinkommen | 467,72 Mio | 95,66% |
EBITDA | 674,78 Mio | 31,45% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 31,90 Mrd€ |
Anzahl Aktien | 241,57 Mio |
52 Wochen-Hoch/Tief | 132,56€ - 82,27€ |
Dividendenrendite | 1,39% |
Dividenden TTM | 1,87€ |
Beta | 0,63 |
KGV (PE Ratio) | 23,03 |
KGWV (PEG Ratio) | 1,18 |
KBV (PB Ratio) | −12,17 |
KUV (PS Ratio) | 0,16 |
Unternehmensprofil
Cardinal Health, Inc. ist als Unternehmen für integrierte Gesundheitsdienstleistungen und -produkte in den Vereinigten Staaten, Kanada, Europa, Asien und international tätig. Das Unternehmen bietet maßgeschneiderte Lösungen für Krankenhäuser, Gesundheitssysteme, Apotheken, ambulante Operationszentren, klinische Labors, Arztpraxen und Patienten zu Hause. Das Unternehmen ist in zwei Segmenten tätig: Pharmazeutika und Medizintechnik. Das Segment Pharmazeutik vertreibt Marken- und Generikaprodukte, Spezialpharmazeutika sowie rezeptfreie Gesundheits- und Verbraucherprodukte. Das Segment bietet außerdem Dienstleistungen für pharmazeutische Hersteller und Gesundheitsdienstleister für pharmazeutische Spezialprodukte an, betreibt Nuklearapotheken und radiopharmazeutische Produktionsanlagen, verpackt generische Arzneimittel und rezeptfreie Gesundheitsprodukte neu und bietet Krankenhäusern, anderen Gesundheitsdienstleistern und Kostenträgern Dienstleistungen in den Bereichen Medikationstherapiemanagement und Patientenresultate sowie Apothekenmanagement für Krankenhäuser an. Das Segment Medizintechnik produziert, beschafft und vertreibt medizinische, chirurgische und Laborprodukte und -geräte der Marke Cardinal Health, darunter Untersuchungs- und Operationshandschuhe, Nadeln, Spritzen und Entsorgungssysteme für scharfe Gegenstände, Kompressen, Inkontinenzprodukte, Produkte für die Nährstoffversorgung, Produkte für die Wundversorgung, Einweg-Operationsabdeckungen, -kittel und -kleidung, Flüssigkeitsabsaug- und -entnahmesysteme, urologische Produkte, Produkte für die Versorgung von Operationssälen und Elektroden. Das Segment vertreibt auch eine Reihe von nationalen Markenprodukten, einschließlich medizinischer, chirurgischer und Laborprodukte; es bietet Versorgungskettendienstleistungen und -lösungen für Krankenhäuser, ambulante Operationszentren, klinische Labors und andere Gesundheitsdienstleister an und stellt sterile und nicht sterile Behandlungssets zusammen und verkauft sie. Das Unternehmen hat eine Kooperationsvereinbarung mit Journey Biosciences, Inc. Cardinal Health, Inc. wurde 1979 gegründet und hat seinen Hauptsitz in Dublin, Ohio.
Name | Cardinal Health |
CEO | Jason M. Hollar |
Sitz | Dublin, oh USA |
Website | |
Industrie | Pharmazie |
Börsengang | |
Mitarbeiter | 47.922 |
Ticker Symbole
Börse | Symbol |
---|---|
NYSE | CAH |
London Stock Exchange | 0HTG.L |
Frankfurt | CLH.F |
Düsseldorf | CLH.DU |
London | 0HTG.L |
SIX | CLH.SW |
München | CLH.MU |
Assets entdecken
Shareholder von Cardinal Health investieren auch in folgende Assets